Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLR 131 in Children, Adolescents, and Young Adults With Select Solid Tumors, Lymphoma, and Malignant Brain Tumors
NCT03478462Phase 1Active, not recruiting
- Sponsor
- Cellectar Biosciences
- Start
- Apr 2019
- Primary completion
- Jun 2027
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of Iopofosine I-131 in solid tumor, lymphoma, brain tumor and 5 more, sponsored by Cellectar Biosciences. Primary endpoint: Number of participants with dose limiting toxicities up to 64 days. Started Apr 2019; status: active, not recruiting.
02
Drugs
Iopofosine I-131
03
Conditions
solid tumorlymphomabrain tumordiffuse intrinsic pontine glioma (DIPG)neuroblastoma
Beyond the preview
Go deeper on NCT03478462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03478462.